SL
NMRA icon

Siren LLC’s Neumora Therapeutics NMRA Stock Holding History

Siren LLC’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.4M Hold
8,497,822
– – 0.29% 60
2026
Q1 		$16.6M Buy
8,497,822
+2,209,039
+35% +$5.72M 0.46% 47
2025
Q4 		$11.3M Buy
6,288,783
+1,930,500
+44% +$4.23M 0.34% 51
2025
Q3 		$7.93M Hold
4,358,283
– – 0.31% 53
2025
Q2 		$3.2M Hold
4,358,283
– – 0.17% 76
2025
Q1 		$4.36M Sell
4,358,283
-37,817
-0.9% -$64.8K 0.25% 59
2024
Q4 		$46.6M Buy
4,396,100
+1,789,529
+69% +$21.4M 2.06% 13
2024
Q3 		$34.4M Buy
+2,606,571
New +$30.4M 1.72% 19

Other funds holding NMRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Siren LLC's NMRA Position: Q2 2026 in Review

Siren LLC held its Neumora Therapeutics (NMRA) position steady in Q2 2026 at 8,497,822 shares worth $14.4M. The position accounts for 0.29% of the portfolio, ranked #60.

Siren LLC first reported a position in NMRA in Q3 2024 and has held it in 8 quarters since. The position peaked at $46.6M in Q4 2024. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • Siren LLC held 8,497,822 shares of Neumora Therapeutics worth $14.4M as of Q2 2026.
  • Siren LLC left its Neumora Therapeutics share count unchanged in Q2 2026.
  • Neumora Therapeutics made up 0.29% of Siren LLC's portfolio in Q2 2026, its #60 holding.
  • Siren LLC first reported a position in Neumora Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Siren LLC's Neumora Therapeutics position peaked at $46.6M in Q4 2024.
  • 113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on Siren LLC's 13F filing for Q2 2026, filed 13 Aug 2026.